Renin-angiotensin blockade in diabetic retinopathy

International Journal of Clinical Practice

Volumn 65, Issue 2, 2011, Pages 113-116

  Ghattas, A ^a   Lip, P L ^b   Lip, G Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b CITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; PRORENIN; RENIN; STEROID; VASCULOTROPIN INHIBITOR;

BLINDNESS; DIABETES MELLITUS; DIABETIC RETINOPATHY; EYE INFECTION; EYE INFLAMMATION; HUMAN; LASER COAGULATION; NEPHRITIS; OCULAR FIBROSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA BLOOD VESSEL; RETINA DETACHMENT; RETINA MACULA EDEMA; RETINOPATHY; REVIEW;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; HUMANS; RENIN-ANGIOTENSIN SYSTEM;

EID: 78751548454     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2010.02592.x     Document Type: Review

References (24)

1. The EURODIAB IDDM complications study group. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications study. Diabetologia 1994; 37: 278-85.
2. SjÃlie AK,. Prospects for angiotensin receptor blockers in diabetic retinopathy. Diab Res Clin Prac 2007; 76S: S31-39.
3. Early Photocoagulation for diabetic retinopathy. ETDRS report number 9. Early treatment Diabetic Retinopathy Study Group. Opthalmol 1991; 98 (5 Suppl.): 766-785.
4. Paul M., Poyan Mehr A., Kreutz R,. Physiology of local renin-angiotensin systems. Physiol Rev 2006; 86: 747-80.
5. SjÃlie AK, Dodson P, Hobbs R,. Does renin-angiotensin system blockade have a role in preventing diabetic retinopathy? A clinical review. Int J Clin Pract 2011; 65: 148-53.
6. Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 1998; 351: 28-31.
7. SjÃlie AK, Klein R, Porta M, et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008; 372: 1385-93.
8. Chaturvedi N, Porta M, Klein R, et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008; 372: 1394-402.
9. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009; 361: 40-51.
10. The Diabetes Control and Complications Trial research Group. The effect of intensive treatment of diabetes on the development and progression of longterm complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
11. Younis N, Broadbent DM, Harding SP, Vora JP,. Incidence of sight-threatening retinopathy in type 1 diabetes in a systematic screening programme. Diabet Med 2003; 20: 758-65.
12. Ganten D., Minnich J.L., Granger P, et al. Angiotensinforming enzyme in brain tissue. Science, 1971; 173: 64-65.
13. Fletcher E, Phipps J, Ward M, Vessey K, Willson-Berka J,. The renin angiotensin system in retina l health and disease: its influence on neurones, glia and the vasulature. Prog Ret Eye Res 2010; 29: 284-311.
14. Steckelimgs UM, Rompe F, Kaschina E, Unger T,. He evolving story of the RAAS in hypertension, diabetes and CV disease- moving from macrovascular to microvascualr targets. Fund Clin Pharmacol 2009; 23: 693-703.
15. Miller AG, Tan G, Binger KJ, et al. Candesartan attenuates diabetic retinal vascular pathology by restoring Glyoxalase-1 function. Diabetes 2010; 59: 3208-3215.
16. Hsieh T.J., Fustier P., Zhang S.L., et al. High glucose stimulates angiotensinogen gene expression and cell hypertrophy via activation of the hexosamine biosynthesis pathway in rat kidney proximal tubular cells. Endocrinology 2003; 144: 4338-4349.
17. Brownlee M,. Banting lecture 2004. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-25.
18. Kim HW, Kim JL, Lee HK, Hur DY, Yun IH, Kim SD,. Enalapril alters expression of key growth factors in experimental diabetic retinopathy. Curr Eye Res 2009; 34: 976-87.
19. Malhotra A, Kang BP, Cheung S, Opawumi D, Meggs LG,. Angiotensin II promotes glucose-induced activation of cardiac protein kinase C isozymes and phosphorylation of troponin I. Diabetes 2001; 50: 1918-26.
20. Chen S., Zivadeh F.N,. Vascular endothelial growth factor and diabetic nephropathy. Curr Diab Rep 2008; 8: 470-6.
21. Schweighofer B, Testori J, Sturtzel C, et al. The VEGF-induced transcriptional response comprises gene clusters at the crossroad of angiogenesis and inflammation. Thromb Haemost 2009; 102: 544-54.
22. Kurihara T, Ozawa Y, Nagai N, et al. Angiotensin II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina. Diabetes 2008; 57: 2191-8.
23. Wilkinson-Berka JL, Campbell DJ,. (Pro)renin receptor: a treatment target for diabetic retinopathy? Diabetes 2009; 58: 1485-7.
24. Wilkinson-Berka JL, Tan G, Jaworski K, Miller AG,. Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology. Circ Res 2009; 104: 124-33.